Discover what Emgality® can do for patients with episodic migraine1
For your patients with 4-14 MHDs per month,1

Meet Jessicaa
AGE: 38
CLINICAL FACTORS
- 4 or more unpredictable migraine headache days (MHDs) per month
- Has tried therapeutic doses of 2 standard-of-care generic preventives
- May now be only relying on her acute treatments
NON-CLINICAL FACTORS
- Isn’t sure another preventive will give her the results she is looking for
aHypothetical patient profile.
“Even though I try to stay positive and push through, migraine continues to impact my work and my personal life. It’s important to me to find a treatment regimen that fits into my life because my family depends on me.”
— Jessica, hypothetical patient with episodic migraine
Review safety profile or the results from the 12-month, open-label safety study for Emgality
References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0120. 3. Data on File. Lilly USA, LLC. DOF-GZ-US-0002. 4. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088. 5. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. 6. Aimovig [Prescribing Information]. Thousand Oaks, CA: Amgen Inc.; 2019. 7. Ajovy [Prescribing Information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2019. 8. Vyepti [Prescribing Information]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.; 2020. 9. Data on File. Lilly USA, LLC. DOF-GZ-US-0147. 10. Data on File. Lilly USA, LLC. DOF-GZ-US-0148. 11. Data on File. Lilly USA, LLC. DOF-GZ-US-0012. 12. Data on File. Lilly USA, LLC. DOF-GZ-US-0010. 13. Bagley CL, Rendas-Baum R, Maglinte GA, et al. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52:409-421. 14. Data on File. Lilly USA, LLC. DOF-GZ-US-0025. 15. Data on File. Lilly USA, LLC. DOF-GZ-US-0015. 16. Data on File. Lilly USA, LLC. DOF-GZ-US-0016. 17. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update:pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78:1337-1345. 18. Data on File. Lilly USA, LLC. DOF-GZ-US-0092. 19. Data on File. Lilly USA, LLC. DOF-GZ-US-0091. 20. Data on File. Lilly USA, LLC. DOF-GZ-US-0090. 21. Data on File. Lilly USA, LLC. DOF-GZ-US-0084. 22. Data on File. Lilly USA, LLC. DOF-GZ-US-0024.